Abbott Laboratories (ABT) Total Non-Current Liabilities (2009 - 2021)

Abbott Laboratories (ABT) has 13 years of Total Non-Current Liabilities data on file, last reported at $4.0 billion in Q4 2021.

• For the quarter ending Q4 2021, Total Non-Current Liabilities rose 2048.54% year-over-year to $4.0 billion; the trailing twelve-month figure through Dec 2021 stood at $4.0 billion (up 2048.54% YoY), and the FY2021 full-year result was $4.0 billion, up 2048.54% from the prior year.
• Total Non-Current Liabilities rose to $4.0 billion in Q4 2021, from -$206.0 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $71.4 billion in Q4 2017 to a low of -$670.0 million in Q4 2019.
• A 5-year average of $27.5 billion and a median of $4.0 billion in 2021 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities slumped 101.06% in 2019 and surged 2048.54% in 2021, its largest moves.
• Tracing ABT's Total Non-Current Liabilities over 5 years: stood at $71.4 billion in 2017, then slipped by 11.49% to $63.2 billion in 2018, then sank by 101.06% to -$670.0 million in 2019, then soared by 69.25% to -$206.0 million in 2020, then surged by 2048.54% to $4.0 billion in 2021.
• Business Quant data shows ABT's Total Non-Current Liabilities at $4.0 billion in Q4 2021, -$206.0 million in Q4 2020, and -$670.0 million in Q4 2019.